Hospital
Doctors Medical Center of Modesto, INC.
Doctors Medical Center of Modesto, INC. was paid $61.42M by Medicaid between Jan 2018 and Dec 2024, across 342 billing codes. Its largest line is 0450, Emergency room services — 32% of everything it billed.
33Billing provider infoDOCTORS MEDICAL CENTER OF MODESTO, INC.
TURLOCK, CA 95382
TURLOCK, CA 95382
33aNPI1396087672assigned 03/25/2013
33bProvider typeGeneral Acute Care Hospital
28Total paid$61.42M
24GClaims1,405,254
24DCodes billed342
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in California
Rank by total paid#50 of 410
Median peer was paid$6.90M
This provider vs. median8.9×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 255,473 | $8.62M | |
| 2019 | 235,847 | $7.32M | |
| 2020 | 196,075 | $6.72M | |
| 2021 | 165,864 | $8.50M | |
| 2022 | 178,393 | $10.19M | |
| 2023 | 200,889 | $10.94M | |
| 2024incomplete | 172,713 | $9.14M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 0450 | Emergency room services | 32% | 127,720 | 114,355 | $19.72M |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 6.0% | 65,338 | 59,692 | $3.67M |
| J2505 | Injection, pegfilgrastim, 6 mg | 3.0% | 225 | 149 | $1.85M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.5% | 7,226 | 7,092 | $1.51M |
| J1453 | Injection, fosaprepitant, 1 mg | 2.4% | 3,296 | 1,580 | $1.50M |
| 78815 | Positron emission tomography (PET) for limited area imaging | 2.1% | 810 | 804 | $1.31M |
| J0897 | Injection, denosumab, 1 mg | 2.0% | 724 | 528 | $1.26M |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 1.8% | 7,348 | 7,183 | $1.11M |
| 80053 | Comprehensive metabolic panel | 1.8% | 100,192 | 84,825 | $1.10M |
| 70450 | Computed tomography, head or brain; without contrast material | 1.8% | 8,259 | 8,049 | $1.09M |
| 77067 | Screening mammography, bilateral, including computer-aided detection | 1.6% | 9,363 | 9,345 | $1.01M |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | 1.4% | 6,959 | 4,272 | $888K |
330 more codes
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.3% | 12,599 | $786K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 1.2% | 13,551 | $728K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.2% | 105,987 | $714K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.1% | 27,559 | $673K |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.1% | 16,867 | $650K |
| Z7502 | <1% | 15,619 | $582K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 19,370 | $577K |
| 97139 | <1% | 25,633 | $567K | |
| J3490 | Unclassified drugs | <1% | 21,880 | $555K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 4,654 | $523K |
| 71045 | Radiologic examination, chest; single view | <1% | 20,735 | $513K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 1,597 | $506K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 6,629 | $503K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 7,006 | $477K |
| T1999 | Miscellaneous therapeutic items and supplies, retail purchases, not otherwise classified; identify product in "remarks" | <1% | 48,441 | $453K |
| J9271 | Injection, pembrolizumab, 1 mg | <1% | 31 | $418K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 5,956 | $413K |
| 97799 | <1% | 16,818 | $411K | |
| 99283 | Emergency room visit (moderate) | <1% | 3,185 | $385K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 13,901 | $356K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 7,503 | $353K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 11,210 | $328K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 4,826 | $324K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 4,911 | $315K |
| 99284 | Emergency room visit (serious) | <1% | 3,494 | $309K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 1,761 | $295K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 1,506 | $277K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 11,050 | $272K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 9,671 | $260K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 4,619 | $253K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 8,520 | $249K |
| 77065 | Tomosynthesis, mammo | <1% | 2,268 | $247K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 7,505 | $243K |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | <1% | 773 | $240K |
| 84484 | <1% | 23,606 | $233K | |
| 83735 | <1% | 33,020 | $228K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 29,471 | $225K |
| 96367 | <1% | 5,034 | $223K | |
| 76642 | <1% | 3,527 | $216K | |
| 77066 | Tomosynthesis, mammo | <1% | 1,786 | $215K |
| 76801 | <1% | 2,843 | $214K | |
| 93458 | <1% | 325 | $198K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 1,104 | $195K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 14,716 | $187K |
| J9267 | Injection, paclitaxel, 1 mg | <1% | 632 | $184K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 2,680 | $181K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 14,626 | $170K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 4,026 | $166K |
| J1626 | Injection, granisetron hydrochloride, 100 mcg | <1% | 5,603 | $165K |
| 83880 | <1% | 7,994 | $164K | |
| 83690 | <1% | 23,333 | $159K | |
| 97750 | <1% | 2,810 | $148K | |
| 93971 | <1% | 1,494 | $147K | |
| 0160 | <1% | 163 | $146K | |
| 0510 | <1% | 5,527 | $144K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 5,603 | $143K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 2,865 | $137K |
| 0762 | <1% | 135 | $135K | |
| 96417 | <1% | 3,467 | $134K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 3,448 | $123K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 3,426 | $123K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 8,323 | $118K |
| 59025 | Fetal non-stress test | <1% | 3,699 | $117K |
| 81001 | <1% | 32,840 | $116K | |
| 0761 | <1% | 3,665 | $115K | |
| 99285 | Emergency room visit (most serious) | <1% | 1,760 | $111K |
| Q3014 | Telehealth originating site facility fee | <1% | 4,894 | $107K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 10,941 | $106K |
| 76830 | Ultrasound, transvaginal | <1% | 1,362 | $103K |
| J1950 | Injection, leuprolide acetate (for depot suspension), per 3.75 mg | <1% | 53 | $100K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 1,568 | $96K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 11,238 | $90K |
| 87040 | <1% | 5,950 | $89K | |
| 96415 | <1% | 2,897 | $86K | |
| J3489 | Injection, zoledronic acid, 1 mg | <1% | 555 | $84K |
| 73610 | <1% | 2,308 | $84K | |
| 0259 | <1% | 2,198 | $80K | |
| 73630 | <1% | 2,357 | $75K | |
| 83605 | <1% | 6,794 | $75K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 541 | $73K |
| 73562 | <1% | 2,295 | $73K | |
| 82378 | <1% | 4,550 | $72K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 4,515 | $68K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 461 | $68K |
| 84703 | <1% | 9,116 | $67K | |
| 73030 | <1% | 1,991 | $67K | |
| 62323 | <1% | 60 | $66K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 560 | $65K |
| 29125 | <1% | 389 | $65K | |
| 0760 | <1% | 2,093 | $64K | |
| 73130 | <1% | 1,916 | $62K | |
| 81025 | <1% | 8,407 | $61K | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 344 | $61K |
| 87088 | <1% | 8,844 | $61K | |
| 84702 | <1% | 4,343 | $60K | |
| 0270 | <1% | 4,834 | $60K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 1,570 | $60K |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 5,447 | $58K |
| 87631 | <1% | 1,043 | $56K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 7,608 | $56K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 1,593 | $53K |
| 73110 | <1% | 1,572 | $51K | |
| 85730 | <1% | 10,317 | $51K | |
| 0272 | <1% | 1,620 | $50K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 2,381 | $50K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 620 | $49K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 5,659 | $49K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 4,013 | $48K |
| 85610 | <1% | 13,591 | $47K | |
| 12001 | <1% | 265 | $47K | |
| J0640 | Injection, leucovorin calcium, per 50 mg | <1% | 530 | $46K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 3,780 | $46K |
| 90715 | <1% | 1,063 | $45K | |
| J9190 | Injection, fluorouracil, 500 mg | <1% | 1,269 | $45K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 200 | $44K |
| J8499 | Prescription drug, oral, non chemotherapeutic, nos | <1% | 5,629 | $44K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 4,025 | $43K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 1,258 | $42K |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 298 | $41K |
| 87186 | <1% | 4,576 | $39K | |
| Z9725 | <1% | 1,289 | $39K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 10,781 | $38K |
| 29515 | <1% | 247 | $36K | |
| 74018 | <1% | 927 | $36K | |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 34 | $35K |
| 87634 | <1% | 548 | $34K | |
| 82607 | <1% | 2,756 | $33K | |
| J1442 | Injection, filgrastim (g-csf), excludes biosimilars, 1 microgram | <1% | 134 | $33K |
| 86300 | <1% | 3,278 | $33K | |
| 81003 | <1% | 13,247 | $32K | |
| J9263 | Injection, oxaliplatin, 0.5 mg | <1% | 82 | $32K |
| 97010 | <1% | 683 | $31K | |
| 86301 | <1% | 1,942 | $31K | |
| 82728 | <1% | 2,732 | $31K | |
| 85379 | <1% | 3,239 | $31K | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 4,009 | $30K |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 1,069 | $28K |
| 96416 | <1% | 534 | $27K | |
| 85027 | <1% | 4,406 | $27K | |
| 87081 | <1% | 4,044 | $27K | |
| 86141 | <1% | 2,217 | $26K | |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 2,407 | $26K |
| 93970 | <1% | 161 | $25K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 634 | $25K |
| J1815 | Injection, insulin, per 5 units | <1% | 663 | $24K |
| 87632 | <1% | 132 | $24K | |
| 82077 | <1% | 298 | $23K | |
| 77061 | <1% | 480 | $23K | |
| 77336 | <1% | 542 | $23K | |
| 97161 | <1% | 628 | $22K | |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | <1% | 345 | $21K |
| 0360 | <1% | 289 | $21K | |
| 73080 | <1% | 602 | $21K | |
| 96523 | <1% | 481 | $21K | |
| J9045 | Injection, carboplatin, 50 mg | <1% | 274 | $21K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 1,403 | $20K |
| 72100 | <1% | 696 | $20K | |
| 87506 | <1% | 86 | $19K | |
| 84145 | <1% | 1,187 | $19K | |
| 72131 | <1% | 130 | $19K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 1,466 | $18K |
| 37252 | <1% | 219 | $18K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 402 | $18K |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 1,778 | $18K |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 1,970 | $18K |
| 86850 | <1% | 2,822 | $18K | |
| Z7610 | <1% | 2,037 | $17K | |
| 76870 | <1% | 245 | $16K | |
| 86901 | <1% | 5,148 | $16K | |
| 80143 | <1% | 159 | $16K | |
| 77412 | <1% | 250 | $16K | |
| 97165 | <1% | 248 | $16K | |
| 76641 | <1% | 157 | $16K | |
| 77334 | <1% | 72 | $15K | |
| 80179 | <1% | 153 | $15K | |
| 73590 | <1% | 540 | $15K | |
| 86900 | <1% | 5,180 | $15K | |
| 71250 | <1% | 89 | $15K | |
| 82550 | <1% | 2,660 | $15K | |
| 96411 | <1% | 679 | $14K | |
| 84439 | <1% | 1,683 | $14K | |
| 77085 | <1% | 281 | $14K | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 2,238 | $14K |
| 73090 | <1% | 526 | $14K | |
| 96368 | <1% | 685 | $13K | |
| 82948 | <1% | 3,430 | $12K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,545 | $12K |
| 94664 | <1% | 872 | $12K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 1,486 | $12K |
| 93017 | <1% | 341 | $11K | |
| 82803 | <1% | 583 | $11K | |
| 77080 | <1% | 350 | $10K | |
| 87420 | <1% | 1,332 | $10K | |
| 80061 | Lipid panel | <1% | 974 | $10K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 2,181 | $10K |
| 82962 | <1% | 2,511 | $9K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 1,206 | $9K |
| 87210 | <1% | 1,820 | $9K | |
| 70486 | <1% | 61 | $9K | |
| 86304 | <1% | 573 | $9K | |
| 82805 | <1% | 245 | $9K | |
| 87641 | <1% | 459 | $9K | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 949 | $8K |
| 86140 | <1% | 1,696 | $8K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 1,510 | $8K |
| 84466 | <1% | 624 | $7K | |
| 82746 | <1% | 631 | $7K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 1,592 | $7K |
| 96402 | <1% | 458 | $7K | |
| 77300 | <1% | 40 | $7K | |
| 86780 | <1% | 649 | $7K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 26 | $7K |
| 83540 | <1% | 1,208 | $7K | |
| 29105 | <1% | 42 | $7K | |
| 85007 | <1% | 2,080 | $7K | |
| 37253 | <1% | 179 | $6K | |
| 74019 | <1% | 269 | $6K | |
| 87806 | <1% | 222 | $6K | |
| 85611 | <1% | 1,956 | $6K | |
| 70491 | <1% | 24 | $6K | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 945 | $6K |
| 37238 | <1% | 147 | $6K | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 146 | $6K |
| 10060 | <1% | 30 | $5K | |
| 73140 | <1% | 296 | $5K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 60 | $4K |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 412 | $4K |
| 72040 | <1% | 159 | $4K | |
| 85652 | <1% | 1,378 | $4K | |
| 87077 | <1% | 667 | $4K | |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | <1% | 12 | $4K |
| 84100 | <1% | 1,065 | $4K | |
| 99199 | Unlisted special service, procedure or report | <1% | 74 | $4K |
| 73502 | <1% | 141 | $3K | |
| 85651 | <1% | 1,048 | $3K | |
| 75822 | <1% | 55 | $3K | |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 26 | $3K |
| 87147 | <1% | 567 | $3K | |
| 82010 | <1% | 364 | $3K | |
| 0301 | <1% | 39 | $3K | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 193 | $3K |
| 77062 | <1% | 52 | $3K | |
| 86592 | <1% | 502 | $3K | |
| 76775 | <1% | 51 | $3K | |
| 82248 | <1% | 450 | $2K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 447 | $2K |
| J0561 | Injection, penicillin g benzathine, 100,000 units | <1% | 14 | $2K |
| 71020 | <1% | 73 | $2K | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 13 | $2K |
| J0500 | Injection, dicyclomine hcl, up to 20 mg | <1% | 26 | $2K |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 230 | $2K |
| 82140 | <1% | 142 | $2K | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 114 | $2K |
| 82784 | <1% | 241 | $2K | |
| 0250 | <1% | 734 | $2K | |
| 82150 | <1% | 285 | $2K | |
| 85732 | <1% | 272 | $2K | |
| 87045 | <1% | 160 | $2K | |
| 92523 | <1% | 12 | $1K | |
| 71010 | <1% | 84 | $1K | |
| 92557 | <1% | 32 | $1K | |
| S0164 | Injection, pantoprazole sodium, 40 mg | <1% | 114 | $1K |
| 71101 | <1% | 41 | $1K | |
| 82247 | <1% | 259 | $1K | |
| 12011 | <1% | 86 | $1K | |
| 72020 | <1% | 296 | $1K | |
| 83615 | <1% | 174 | $1K | |
| 96376 | <1% | 12 | $1K | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 29 | $986.83 |
| 86920 | <1% | 13 | $982.02 | |
| 73564 | <1% | 41 | $956.21 | |
| 69210 | <1% | 180 | $954.54 | |
| 84165 | <1% | 223 | $937.38 | |
| J1720 | Injection, hydrocortisone sodium succinate, up to 100 mg | <1% | 28 | $927.11 |
| 83521 | <1% | 40 | $906.10 | |
| 87046 | <1% | 157 | $862.69 | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 65 | $861.58 |
| 37239 | <1% | 27 | $851.77 | |
| 36010 | <1% | 92 | $809.16 | |
| J2305 | Injection, nitroglycerin, 5 mg | <1% | 49 | $791.98 |
| 0324 | <1% | 86 | $733.64 | |
| 86334 | <1% | 203 | $725.68 | |
| 84550 | <1% | 157 | $703.88 | |
| 87999 | <1% | 33 | $692.71 | |
| 83655 | <1% | 193 | $629.18 | |
| Z7500 | <1% | 21 | $613.80 | |
| 86703 | <1% | 50 | $587.98 | |
| 92588 | <1% | 12 | $574.45 | |
| S0077 | Injection, clindamycin phosphate, 300 mg | <1% | 29 | $540.50 |
| 0710 | <1% | 25 | $522.82 | |
| 81002 | <1% | 406 | $522.77 | |
| 80074 | <1% | 12 | $461.31 | |
| 72072 | <1% | 14 | $453.16 | |
| 87070 | <1% | 46 | $451.37 | |
| 12002 | <1% | 39 | $447.85 | |
| 82565 | <1% | 95 | $391.94 | |
| 87467 | <1% | 12 | $389.84 | |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | <1% | 34 | $384.11 |
| 73552 | <1% | 25 | $380.27 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 43 | $362.80 |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 59 | $328.37 |
| 86706 | <1% | 45 | $324.86 | |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 13 | $292.40 |
| 99001 | <1% | 290 | $292.27 | |
| 92570 | <1% | 12 | $289.84 | |
| 92504 | <1% | 15 | $285.92 | |
| 73560 | <1% | 12 | $248.63 | |
| 86705 | <1% | 28 | $234.25 | |
| 86308 | <1% | 45 | $229.71 | |
| J2704 | Injection, propofol, 10 mg | <1% | 92 | $212.57 |
| 19083 | <1% | 13 | $188.80 | |
| 84155 | <1% | 79 | $177.85 | |
| 89055 | <1% | 33 | $151.97 | |
| J2470 | Injection, pantoprazole sodium, 40 mg | <1% | 15 | $97.12 |
| 29130 | <1% | 12 | $88.27 | |
| 86331 | <1% | 12 | $88.25 | |
| 96379 | <1% | 4,097 | $87.75 | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 219 | $74.11 |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 16 | $73.35 |
| G0283 | Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | <1% | 164 | $61.37 |
| 87205 | <1% | 13 | $44.63 | |
| J7611 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, concentrated form, 1 mg | <1% | 76 | $38.98 |
| 84156 | <1% | 14 | $28.95 | |
| 86038 | <1% | 12 | $25.67 | |
| 0258 | <1% | 1,823 | $3.09 | |
| 99152 | 0% | 89 | $0.00 | |
| 97116 | 0% | 28 | $0.00 | |
| 0258R | 0% | 208 | $0.00 | |
| 0250R | 0% | 57 | $0.00 | |
| A9270 | Non-covered item or service | 0% | 50 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialGIORGIANI, ROB (CFO)
| Provider | Location | Paid |
|---|---|---|
| Doctors Hospital of Manteca, INC. | Manteca, CA | $23.54M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.